Molecular follow-up of first-line treatment by osimertinib in lung cancer: importance of using appropriate tools for detecting EGFR resistance mutation C797S

Tyrosine kinase inhibitors (TKI) targeting the epidermal growth factor receptor (EGFR) have dramatically improved the response rate and progression free survival (PFS) of patients with EGFR-mutated non-small cell lung carcinoma (NSCLC) [1]. Detection of alterations in the DNA sequence of exons 18-21 of EGFR are currently done by molecular biology platforms worldwide in order to identify patients who will strongly benefit from such a treatment. Notably, small in-frame deletions in exon 19 and point mutations in exon 21, such as L858R, are the most frequent predictive biomarkers of response.

Source: Cancer Genetics and Cytogenetics - June 9, 2021 Category: Genetics & Stem Cells Authors: Y. Fanjat, H. Barazzutti, I. Di Mauro, L. Tabary Martin, V. Duranton-Tanneur, S. Gimet, H. B érard, F. Pedeutour Tags: BRIEF COMMUNICATION Source Type: research